How to optimize the structure of Kangrui Pharmaceutical after continuous mergers and acquisitions

Strengthen the integration of mergers and acquisitions and release the ability of operational development. The continuous M&A of Kangrui Pharmaceutical Co., Ltd. has reduced the operational capacity of Kangrui Pharmaceutical Co., Ltd. to a certain extent. In the later stage, the integration of M&A should be strengthened to release its operational development capacity. Shandong Kangrui Pharmaceutical Co., Ltd. is a joint-stock enterprise, established in 2004, with a registered capital of 70 million yuan, mainly engaged in the pharmaceutical circulation industry.